357 related articles for article (PubMed ID: 34517429)
1. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
3. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
4. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.
Kim DK; Park JJ; Yang WJ; Doo SW; Kim JH
J Korean Med Sci; 2022 Aug; 37(31):e237. PubMed ID: 35942555
[TBL] [Abstract][Full Text] [Related]
7. Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
Huang YB; Li WL; Sun M; Duan X; Wang YT; Zhang LX; Xin ZH; Yun ZF; Fan B; Li XC
Asian J Androl; 2023; 25(3):366-374. PubMed ID: 35915542
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
9. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Karimi A; Nowroozi A; Alilou S; Amini E
Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
[TBL] [Abstract][Full Text] [Related]
10. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
Klein EA; Li J; Milinovich A; Schold JD; Sharifi N; Kattan MW; Jehi L
J Urol; 2021 Feb; 205(2):441-443. PubMed ID: 32897764
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].
Manolache NG; Mjaess G; Diamand R; Albisinni S; Roumeguère T
Prog Urol; 2022 Dec; 32(16):1421-1430. PubMed ID: 36163317
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy.
Gedeborg R; Loeb S; Styrke J; Kiiski-Berggren R; Garmo H; Stattin P
Int J Cancer; 2022 Dec; 151(11):1925-1934. PubMed ID: 35802468
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
Gedeborg R; Lindhagen L; Loeb S; Styrke J; Garmo H; Stattin P
Scand J Urol; 2022 Apr; 56(2):104-111. PubMed ID: 34939533
[TBL] [Abstract][Full Text] [Related]
14. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
16. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
17. Characteristics in Pediatric Patients with Coronavirus Disease 2019 in Korea.
Seon JY; Jeon WH; Bae SC; Eun BL; Choung JT; Oh IH
J Korean Med Sci; 2021 May; 36(20):e148. PubMed ID: 34032033
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
19. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer.
Bian SX; Kuban DA; Levy LB; Oh J; Choi S; McGuire SE; Frank SJ; Mahmood U; Nguyen PL; Pugh TJ; Lee AK; Hoffman KE
Am J Clin Oncol; 2016 Aug; 39(4):368-73. PubMed ID: 24732810
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
Gedeborg R; Styrke J; Loeb S; Garmo H; Stattin P
PLoS One; 2021; 16(10):e0255966. PubMed ID: 34618806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
